Gastroenterology

Although the use biosimilar infliximab in rheumatoid diseases and inflammatory bowel disease has the potential to reduce the treatment costs, a variety of factors may influence the adoption of biosimilar treatments and their potential impacts on healthcare budgets.

Study Finds Biosimilar Infliximab CT-P13 Effective, Safe in IBD Patients

August 15th 2017

By Jackie Syrop

Article

A recent Spanish study concludes that CT-P13, a biosimilar of reference infliximab that has been approved in Korea, the European Union, and the United States, is efficacious and well tolerated in patients with moderate to severe Crohn’s disease (CD) or ulcerative colitis (UC).

Anti-TNF Agents Improve Outcomes, Raise Risks in East Asian Patients With IBD

August 8th 2017

By Jackie Syrop

Article

The introduction of anti-tumor necrosis factor-alpha agents has improved treatment options for patients with inflammatory bowel disease. However, these agents can also lead to increased vulnerability to infections, development of autoimmune diseases, malignancies, and decreased immunogenicity of vaccinations.

Safety, Efficacy of Biosimilar Switching Not Established, Though Information Gap Narrows

July 21st 2017

By Jackie Syrop

Article

An analysis of 53 switching studies reveals a variable level of good-quality evidence regarding switching from reference drugs to their biosimilars.

Which Medications Will Succeed in the Increasingly Competitive Ulcerative Colitis Market?

July 12th 2017

By Jackie Syrop

Article

Spherix Global Insights’ recently released survey of 103 US gastroenterologists reveals that practitioners project significant growth in the use vedolizumab, golimumab, and Pfizer’s Inflectra, an infliximab biosimilar, for the treatment of ulcerative colitis over the next 6 months.